Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332 | Completed Phase 1

• 1 other identifier: CLEZ763X2201
• Study Type: interventional
• Target: 220
• Locations: 1 country
• Sites: 6

Brief Summary

This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.

Conditions

Type II Diabetes

Keywords

Healthy volunteers,; Diabetes; Glucose; Pharmacokinetics

Outcome Measures

Primary Outcomes (18)

• Number of Patients with adverse events, serious adverse events and death

  An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations.

  Day 28

• Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

• Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

• Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

• Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

• Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

• Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4

• Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10

• Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10

• Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

• Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

• Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

• Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

• Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27

• Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28

• Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28

• Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax)

  Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses

  pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28

• Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test

  4 hour post-dose Day 27

Secondary Outcomes (9)

• Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours)

  Pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day -1, Day 1, Day 27, and Day 28

• 2-hour value of post-prandial glucose

  Day 1 of Part I, Day 1 and day 10 of Part II

• Change from baseline in Fasting C-peptide at Day 27 (Part III)

  Baseline, Day 27

• Change from baseline in Fasting Insulin at Day 27 (Part III)

  Baseline , Day 27

• Change from baseline in fasting plasma glucose at Day 27 (Part III)

  Baseline , Day 27

Study Arms (3)

LEZ763

EXPERIMENTAL

Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

Drug: LEZ763

Placebo

PLACEBO COMPARATOR

Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

Drug: Placebo

Sitagliptin

ACTIVE COMPARATOR

Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

Drug: Sitagliptin

Interventions

Placebo DRUG

Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

Placebo

Sitagliptin DRUG

Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

Sitagliptin

LEZ763 DRUG

LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

LEZ763

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All subjects: (suggest this will reduce duplication)
• Male or female aged 18-65 yr,
• Subjects must weigh at least 50 kg to participate in the study. Body mass index (BMI) must be within the range of 18-37 kg/m2 (inclusive
• Only postmenopausal females or female subjects who report surgical sterilization (women without child bearing potential) will be allowed in this study.
• Subjects with stable conventional sleep-wake cycle
• Normal Healthy Volunteers
• Healthy male or female subjects,
• must be in good health (as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at Screening).
• Type II Diabetic Patients
• Type 2 diabetes diagnosed by American Diabetes Association criteria for at least 3 months prior to screening.
• Patients either drug naïve or on stable dose of metformin (stable dose for at least 4 weeks prior to Screening). The metformin dose should remain constant during the course of the study.
• HbA1c 6.5 to 9.5 % inclusive at screening

You may not qualify if:

• All subjects:
• Smokers (use of tobacco products in the previous 3 months).
• Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
• Significant illness within two weeks prior to dosing.
• Have (or have history of) drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations
• Normal Healthy Volunteers
• History of diabetes, or adrenal disorders.
• Type II Diabetic Patients
• Type 1 diabetes mellitus; positive anti-GAD antibodies; acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (6)

Novartis Investigative Site

Chula Vista, California, 91910, United States

Location

Novartis Investigative Site

Miami, Florida, 33126, United States

Location

Novartis Investigative Site

Orlando, Florida, 32809, United States

Location

Novartis Investigative Site

Cincinnati, Ohio, 45227, United States

Location

Novartis Investigative Site

Knoxville, Tennessee, 37920, United States

Location

Novartis Investigative Site

San Antonio, Texas, 78209, United States

Location

Related Links

• Results for CLEZ763X2201 from the Novartis Clinical Trials website

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Diabetes Mellitus

Interventions

Sitagliptin Phosphate

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrazines

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 12, 2012
• First Posted: June 14, 2012
• Study Start: March 1, 2012
• Primary Completion: September 1, 2013
• Study Completion: September 1, 2013
• Last Updated: December 17, 2020

Record last verified: 2016-03

Locations

US (6)